NuCana (NASDAQ:NCNA) Releases Quarterly Earnings Results

NuCana (NASDAQ:NCNA) issued its earnings results on Thursday. The company reported ($0.10) earnings per share (EPS) for the quarter, Zacks reports.

NuCana Stock Down 4.3%

Shares of NuCana stock opened at $3.34 on Friday. The stock has a market capitalization of $100,200.00, a price-to-earnings ratio of -0.01 and a beta of 1.51. NuCana has a twelve month low of $2.78 and a twelve month high of $330.00. The company has a 50-day simple moving average of $4.29 and a two-hundred day simple moving average of $14.67.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the company. Weiss Ratings reissued a “sell (e+)” rating on shares of NuCana in a research report on Wednesday, October 8th. Wall Street Zen raised NuCana to a “sell” rating in a report on Saturday, August 16th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, NuCana has a consensus rating of “Sell”.

NuCana Company Profile

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells.